Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Expenses (2021 - 2025)

Historic Operating Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $156.8 million.

  • Kiniksa Pharmaceuticals International's Operating Expenses rose 2868.75% to $156.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.8 million, marking a year-over-year increase of 3643.01%. This contributed to the annual value of $468.9 million for FY2024, which is 5868.91% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Operating Expenses of $156.8 million as of Q3 2025, which was up 2868.75% from $136.6 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Operating Expenses peaked at $156.8 million during Q3 2025, and registered a low of $42.8 million during Q3 2021.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median Operating Expenses value was $74.6 million (recorded in 2023), while the average stood at $83.6 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first tumbled by 397.65% in 2022, then soared by 7024.15% in 2024.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Operating Expenses stood at $54.9 million in 2021, then rose by 1.75% to $55.8 million in 2022, then soared by 49.21% to $83.3 million in 2023, then soared by 70.24% to $141.8 million in 2024, then rose by 10.57% to $156.8 million in 2025.
  • Its Operating Expenses was $156.8 million in Q3 2025, compared to $136.6 million in Q2 2025 and $124.5 million in Q1 2025.